- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01742143
Impact de l'ICCAN sur l'achèvement du traitement du cancer et la qualité de vie
Un essai contrôlé randomisé de l'impact de l'ICCAN sur l'achèvement du traitement du cancer et la qualité de vie
The purpose of this study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Francesca Gany, MD, MS
- Numéro de téléphone: 646-888-8054
Sauvegarde des contacts de l'étude
- Nom: Jennifer Leng, MD, MPH
- Numéro de téléphone: 646-888-4243
Lieux d'étude
-
-
New Jersey
-
Basking Ridge, New Jersey, États-Unis, 07920
- Recrutement
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
Contact:
- Francesca Gany, MD, MS
- Numéro de téléphone: 646-888-8054
-
Middletown, New Jersey, États-Unis, 07748
- Recrutement
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Contact:
- Fransecsa Gany, MD, MS
- Numéro de téléphone: 646-888-8054
-
Montvale, New Jersey, États-Unis, 07645
- Recrutement
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
Contact:
- Francesca Gany, MD, MS
- Numéro de téléphone: 646-888-8054
-
-
New York
-
Brooklyn, New York, États-Unis, 11220
- Actif, ne recrute pas
- Lutheran Medical Center
-
Commack, New York, États-Unis, 11725
- Recrutement
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
-
Contact:
- Francesca Gany, MD, MS
- Numéro de téléphone: 646-888-8054
-
Harrison, New York, États-Unis, 10604
- Recrutement
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
Contact:
- Francesca Gany, MD, MS
- Numéro de téléphone: 646-888-8054
-
New York, New York, États-Unis, 10065
- Recrutement
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Francesca Gany, MD, MS
- Numéro de téléphone: 646-888-8054
-
Contact:
- Jennifer Leng, MD, MPH
- Numéro de téléphone: 646-888-4243
-
Chercheur principal:
- Francesca Gany, MD, MS
-
New York, New York, États-Unis, 10035
- Recrutement
- Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
-
Contact:
- Francesca Gany, MD
- Numéro de téléphone: 646-888-8054
-
New York, New York, États-Unis, 10031
- Recrutement
- City College of New York (Data Collection AND Data Analysis)
-
Contact:
- Adriana Espinosa, MD
- Numéro de téléphone: 212-650-8404
- E-mail: aespinosa@ccny.cuny.edu
-
Rockville Centre, New York, États-Unis, 11553
- Recrutement
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
Contact:
- Franscesca Gany, MD, MS
- Numéro de téléphone: 646-888-8054
-
The Bronx, New York, États-Unis
- Actif, ne recrute pas
- Lincoln Hospital and Mental Health Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Eligible cancer patients will be recruited in person by multilingual ICCAN Clinical Research Coordinators for participation in the study at Ralph Lauren Center for Cancer Care and Prevention (RLCCP), Lincoln Hospital (LH) and Lutheran Medical Center (LMC). In the event that MSK staff is not present when an eligible patient is identified. Refinement and Pilot RCT participants will be recruited through MSK Manhattan and OneMSK regional sites's.
La description
Participant Inclusion Criteria:
Patient is eligible if he/she is
- fluent in English, Spanish, or Mandarin
- between the ages of 21-80 years old
- cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
- scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
- planning on remaining in the area for at least 1 year
Clinician is eligible if he/she:
- Has an MD or DO degree
- Is the treating physician providing care to a patient enrolled to the study
ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:
- Is 18 - 85 years of age
- Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
- Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
- Is treated in the NY metropolitan area
- Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income < 200% of federal poverty level)
- Has English or Spanish proficiency
- Agrees to be audio-recorded
ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:
- Is 18 - 85 years of age
- Has stage II-III TNBC
- Treated at MSK Manhattan or OneMSK regional sites
- Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income < 200% of federal poverty level)
- Has English or Spanish proficiency
- Agrees to be audio-recorded
ICCAN-IO process evaluation study team participants only:
- Staff member who serves as an Access Facilitator
- Agrees to be audio-recorded
CCAN-GBM
- Over the age of 18 (per EMR)
- Diagnosed with Glioblastoma (per EMR)
- Has not yet started radiation and concurrent temozolomide treatment (per EMR)
- Has a primary neuro-oncologist at MSK (per EMR)
- Will be undergoing radiation at MSK (per EMR)
- Treatment plan consists of a 6-week or 3-week (hypofractionated) course of radiation and chemotherapy (per EMR)
- Participant or caregiver is fluent in English or Spanish
- Planning on remaining in the tri-state area during the 6 weeks or 3 weeks of radiation and chemotherapy (per self-report)
- Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance (per EMR or self-report), demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit), and/or requests help with SDOH resources or navigation
Participant Exclusion Criteria:
Patient is ineligible if he/she is:
- Diagnosed with Stage IV disease
- Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
- Has another family member already enrolled in ICCAN (as determined by patient report)
ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:
- Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
- Participants or family members who are participating in MSK IHCD studies related to social determinants of health
ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:
- Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
- Participants or family members who are participating in MSK IHCD studies related to social determinants of health at the PI's discretion
ICCAN-GBM
- No recurrences - must be newly diagnosed glioblastoma (per EMR)
- Patients undergoing different treatment regimens from the 15 fraction/3 week or 30 fraction/6 week course of radiation (i.e. patients undergoing 10 fractions of palliative radiation due to poor functional status) (per EMR)
- Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms that require individual treatment) (per EMR or self-report)
- Severe cognitive impairment or fluent aphasia as not to understand the assessment measures, interview, or informed consent, without a health care proxy or caregiver that can assist as indicated by clinician or per judgement of study staff. Completion of assessments with the help of caregivers is acceptable. (per EMR or self-report)
- Has another family member or household member already enrolled in ICCAN (per self-report)
- Already participated in or already completed the ICCAN program (per self-report)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Phase I: Refinement
10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK |
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year. Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance. |
|
Phase II, Arm 1: Usual and Customary Care (U&C)
Participants in this group will receive the same referrals on social and economic resources as ICCAN group. |
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year. Chart review at 3 mo, 6 mo and 1 year, and as needed. |
|
Phase II, Arm 2: ICCAN-IO
Arm 2 will consist of everything in Arm 1 |
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year. Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment completion/adherence
Délai: 1 year
|
The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment. |
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of life
Délai: 1 year
|
depression, and stress (measured through validated scales included in the Cancer Treatment Outcomes |
1 year
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Francesca Gany, MD, MS, Memorial Sloan Kettering Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 12-223
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .